Valuation: Neuronetics, Inc.

Market Cap 167M 150M 138M 125M 234M 15.89B 237M 1.65B 659M 8.32B 626M 613M 26.4B P/E 2026 *
-6.5x
P/E 2027 * -8.07x
Enterprise Value 167M 150M 138M 125M 234M 15.89B 237M 1.65B 659M 8.32B 626M 613M 26.4B EV / Sales 2026 *
1.03x
EV / Sales 2027 * 0.94x
Free-Float
67.15%
Yield 2026 *
-
Yield 2027 * -
1 day+3.20%
1 week+14.14%
Current month-3.42%
1 month-17.52%
3 months+24.86%
6 months+33.73%
Current year+63.77%
1 week 1.98
Extreme 1.98
2.35
1 month 1.84
Extreme 1.84
2.57
Current year 0.8
Extreme 0.8
3.44
1 year 0.8
Extreme 0.8
3.44
3 years 0.52
Extreme 0.52
5.92
5 years 0.52
Extreme 0.52
6.95
10 years 0.52
Extreme 0.52
39.39
Manager TitleAgeSince
Chief Executive Officer 63 23/03/2026
Director of Finance/CFO 51 23/07/2026
Chief Operating Officer 69 19/06/2025
Director TitleAgeSince
Director/Board Member 67 01/07/2017
Director/Board Member 66 01/10/2019
Chairman 71 27/05/2021
Date Insider Type Main position Quantity % Market Cap. Importance
14/08/26 Buy 14,000 0.0212%
23/07/26 Free

Chief Financial Officer

500,000 0.7561%
14/07/26 Buy 35,000 0.0529%
Change 5-day change 1-year change 3-year change Capi.($)
+3.20%+14.14%-26.86%+115.24% 167M
+1.61%+2.44%+24.90%+63.22% 256B
+0.89%+4.38%+5.91%+24.58% 163B
-0.38%+1.41%-19.42%+71.51% 155B
-5.84%-6.91%-58.58%-14.32% 65.3B
+1.06%+3.95%+13.56%+48.73% 52.35B
+1.72%+2.78%-13.92%-7.13% 51.93B
+1.39%-0.27%+7.48%+67.70% 50.75B
+2.25%+4.90%+23.80%+76.59% 50.04B
+1.78%+7.69%+35.57%+94.84% 46.03B
Average +0.90%+2.62%-0.76%+54.10% 89.06B
Weighted average by Cap. +0.85%+1.68%+4.16%+49.59%

Financials

2026 *2027 *
Net sales 162M 145M 134M 122M 227M 15.43B 230M 1.61B 640M 8.07B 608M 595M 25.63B 177M 159M 147M 133M 248M 16.86B 251M 1.76B 699M 8.82B 664M 650M 28B
Net income -25.45M -22.83M -21.11M -19.12M -35.72M -2.42B -36.15M -252M -101M -1.27B -95.5M -93.49M -4.03B -21.7M -19.47M -18M -16.3M -30.46M -2.07B -30.82M -215M -85.72M -1.08B -81.43M -79.71M -3.43B
Net Debt - -
Projected Income Statement - Annual - Neuronetics, Inc.
Logo Neuronetics, Inc.
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
Employees
658
Date Price Change Volume
29/10/26 $2.260 +3.20% 318,709
27/10/26 $2.190 -2.23% 278,261
26/10/26 $2.240 +6.16% 1,098,974
23/10/26 $2.110 +1.44% 600,452
22/10/26 $2.080 +3.48% 788,216
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Neuronetics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.260USD
Average target price
5.750USD
Spread / Average Target
+154.42%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Neuronetics, Inc.
  1. Stock Market
  2. Stocks
  3. STIM Stock